RxDoctor Payments Data

David Crawford, MD

Psychiatry · Madison, WINPI 1053362954

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.7% of the total. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,911in general payments, 2019–2025

Across 278 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$968
  • Alkermes, Inc.$371
  • Lundbeck LLC$324
  • Takeda Pharmaceuticals U.S.A., Inc.$285
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$261
  • Johnson & Johnson$254
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,80097%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,911 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$72,667
Medicare patients
131
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl25$62,989
TrintellixVortioxetine Hydrobromide16$8,411
Quetiapine Fumarate96$4,953
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine137$4,481
Duloxetine Hcl152$4,193
Bupropion XlBupropion Hcl115$3,952
Ziprasidone Hcl45$3,703
Buspirone Hcl138$3,473
Divalproex Sodium42$3,124
Lamotrigine181$2,968
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$2,878
Methylphenidate Hcl Er (Cd)Methylphenidate Hcl23$2,874
Carbamazepine ErCarbamazepine20$2,821
Lisdexamfetamine Dimesylate12$2,788
Doxepin Hcl25$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$968$62,98925 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$285$8,41116 claims
Lilly USA, LLCOlanzapine$23$1,463105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →